Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
Trends in Genitourinary Cancers Examined in the United States
Among non - Hispanic Whites, highest incidence rates seen in Northeast for bladder cancer, Appalachia for kidney cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2022 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Nephrology, Oncology, Urology, Journal, Source Type: news
Trends in Genitourinary Cancers Examined in the United States
WEDNESDAY, Dec. 21, 2022 -- The highest incidence rates of bladder cancer are seen in the Northeast, while the West has the highest deaths rates for prostate cancer among non-Hispanic White men, according to a study published online Dec. 21 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Gene Therapy for Tough - to - Treat Bladder Cancer
About 57,000 men and 18,000 women are diagnosed with bladder cancer annually (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 20, 2022 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, FDA Approvals, Source Type: news
FDA Approves Adstiladrin, Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 -- The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin (nadofaragene firadenovec-vncg), which is designed to work for patients with high-risk non-muscle-invasive bladder cancer (NMIBC)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 19, 2022 Category: General Medicine Source Type: news
FDA Approves Gene Therapy for Tough - to - Treat Bladder Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 19, 2022 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Research, News, Source Type: news
FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu érin unresponsive non-muscle invasive bladder cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 19, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
New FDA-Approved Treatment For Tough-to-Treat Bladder Cancer, Adstiladrin
MONDAY, Dec. 19, 2022 -- Patients with a high-risk bladder cancer now have a new option to treat it.
The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who have... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 19, 2022 Category: General Medicine Source Type: news
FDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 -- Patients with a high-risk bladder cancer now have a new option to treat it.
The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who have what ’s... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 19, 2022 Category: General Medicine Source Type: news
Mesothelioma Surgery With Immunotherapy Proves Effective in Study
An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine.
The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective.
This randomized clinical trial compared the use of durvalumab alone – already shown to be effective in other cancers – to both the two-drug combination and to using no immunotherapy before mesothelioma surgery.
Clinica...
Source: Asbestos and Mesothelioma News - December 19, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Pleural Source Type: news
FDA Approves First Gene Therapy for Bladder Cancer FDA Approves First Gene Therapy for Bladder Cancer
A clinical trial found that half of participants had a complete response to nadofaragene firadenovec (Adstiladrin).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Source: World Pharma News)
Source: World Pharma News - December 16, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer
Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 16, 2022 Category: Drugs & Pharmacology Source Type: news
